drugset / Trial / NCT06915142
A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.
Timeline
- Start
- 2025-04-28
- Primary completion
- 2026-12
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | BP102 | Monoclonal antibody | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | HRS-7058 | Unknown | — | — |
| Subject | SHR-1826 | Unknown | — | — |
| Subject | SHR-9839 | Unknown | — | Subcutaneous |
| Subject | SHR-9839 | Unknown | — | — |
| Subject | SHR-A1202 | Unknown | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |